These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 8081136)

  • 21. Prognostic factors for survival in melanoma patients with brain metastases.
    Davies MA; Liu P; McIntyre S; Kim KB; Papadopoulos N; Hwu WJ; Hwu P; Bedikian A
    Cancer; 2011 Apr; 117(8):1687-96. PubMed ID: 20960525
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Number of primary melanomas is an independent predictor of survival in patients with metastatic melanoma.
    Murali R; Brown PT; Kefford RF; Scolyer RA; Thompson JF; Atkins MB; Long GV
    Cancer; 2012 Sep; 118(18):4519-29. PubMed ID: 22736239
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of Fas ligand (CD95L) in primary malignant melanoma and melanoma metastases is associated with overall survival.
    Neuber K; Eidam B
    Onkologie; 2006 Sep; 29(8-9):361-5. PubMed ID: 16974112
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incidence and thickness of primary tumours and survival of patients with cutaneous malignant melanoma in relation to socioeconomic status.
    MacKie RM; Hole DJ
    BMJ; 1996 May; 312(7039):1125-8. PubMed ID: 8620127
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A retrospective observational study of primary cutaneous malignant melanoma patients treated with excision only compared with excision biopsy followed by wider local excision.
    McKenna DB; Lee RJ; Prescott RJ; Doherty VR
    Br J Dermatol; 2004 Mar; 150(3):523-30. PubMed ID: 15030337
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic model for primary melanoma.
    Jain BP
    Ann Intern Med; 1997 May; 126(10):832. PubMed ID: 9148670
    [No Abstract]   [Full Text] [Related]  

  • 27. Melanoma in people aged 65 and over in Scotland, 1979-89.
    McHenry PM; Hole DJ; MacKie RM
    BMJ; 1992 Mar; 304(6829):746-9. PubMed ID: 1571680
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Survival and prognostic factors in patients with brain metastases from malignant melanoma.
    Meier S; Baumert BG; Maier T; Wellis G; Burg G; Seifert B; Dummer R
    Onkologie; 2004 Apr; 27(2):145-9. PubMed ID: 15138346
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Calculation of survival of patients with stage III melanoma.
    Berd D; Mastrangelo MJ; Sato T
    J Clin Oncol; 2005 Dec; 23(36):9427; author reply 9428. PubMed ID: 16361644
    [No Abstract]   [Full Text] [Related]  

  • 30. Immunosuppression is an independent prognostic factor associated with aggressive tumor behavior in cutaneous melanoma.
    Donahue T; Lee CY; Sanghvi A; Obregon R; Sidiropoulos M; Cooper C; Merkel EA; Yélamos O; Ferris L; Gerami P
    J Am Acad Dermatol; 2015 Sep; 73(3):461-6. PubMed ID: 26209220
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of oncogene expression as an independent prognostic marker for primary melanoma.
    Grover R; Pacifico MD; Wilson GD; Sanders R
    Ann Plast Surg; 2003 Feb; 50(2):183-7. PubMed ID: 12567057
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Primary Tumor Thickness is a Prognostic Factor in Stage IV Melanoma: A Retrospective Study of Primary Tumor Characteristics.
    Luen S; Wong SW; Mar V; Kelly JW; McLean C; McArthur GA; Haydon A
    Am J Clin Oncol; 2018 Jan; 41(1):90-94. PubMed ID: 26325493
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Endogenous immune response to early- and intermediate-stage melanoma is correlated with outcomes and is independent of locoregional relapse and standard prognostic factors.
    Litvak DA; Gupta RK; Yee R; Wanek LA; Ye W; Morton DL
    J Am Coll Surg; 2004 Jan; 198(1):27-35. PubMed ID: 14698308
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Various prognostic factors in malignant melanoma].
    Przywara S; Niepołomska W; Adamus J
    Pol Przegl Chir; 1978 Dec; 50(12):1049-55. PubMed ID: 751021
    [No Abstract]   [Full Text] [Related]  

  • 35. Determinants of unfavorable presentation of primary cutaneous melanoma.
    Fallah M; Kharazmi E; Thomsen H; Sundquist J; Hemminki K
    J Am Acad Dermatol; 2011 Jul; 65(1):e5-6. PubMed ID: 21679807
    [No Abstract]   [Full Text] [Related]  

  • 36. Does childhood vaccination and exposure to infection improve long-term survival in patients with malignant melanoma?
    Tarhini AA; Land S; Gupta A; Kirkwood JM
    Nat Clin Pract Oncol; 2005 May; 2(5):240-1. PubMed ID: 16264957
    [No Abstract]   [Full Text] [Related]  

  • 37. [Multivariation analysis of the importance of prognostic factors in stage I malignant melanoma (proceedings)].
    Boeryd B; Eldh J; Peterson LE
    Lakartidningen; 1978 Dec; 75(49):4597-8. PubMed ID: 723349
    [No Abstract]   [Full Text] [Related]  

  • 38. 18FDG-PET to assess recurrence and long term survival in patients with malignant melanoma.
    Wieder HA; Tekin G; Rosenbaum-Krumme S; Klode J; Altenbernd J; Bockisch A; Nagarajah J
    Nuklearmedizin; 2013; 52(5):198-203. PubMed ID: 23969722
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Different natural course of disease in patients with melanoma.
    Hocevar M; Peric B; Besic N; Zgajnar J
    J Clin Oncol; 2009 Feb; 27(6):998; author reply 999. PubMed ID: 19164201
    [No Abstract]   [Full Text] [Related]  

  • 40. Survival of Danish cancer patients 1943-1987. Malignant melanoma of the skin.
    Osterlind A; Kjems E
    APMIS Suppl; 1993; 33():149-55. PubMed ID: 8512737
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.